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Introduction
Inflammatory bowel diseases (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), are 
chronic, inflammatory conditions of  the bowel with pathogenesis driven by both genetic and environmental 
risk factors. Physical manifestations of  disease range from discontinuous patterns of  inflammation along 
the entire gastrointestinal tract in CD to localized but continuous inflammation of  colon in UC. GWAS 
have uncovered more than 200 SNP-tagged regions as associated with IBD, implicating several hundred 
genes as being possibly associated with disease. (1). However, there has been a critical lack of  characteriza-
tion of  expression of  these disease-associated genes in the tissue that is directly targeted in IBD.
Two approaches to determine candidate genes within risk loci include the study of  tissue- and dis-
ease-specific differential gene expression and the characterization of  expression quantitative trait loci 
(eQTLs) effects. To date, the largest gene expression studies in IBD-relevant tissues were analyzed on 
microarray platforms, but approximately 23% of  the genes now of  interest in IBD were not captured by 
these methods (2, 3). eQTL analyses associate SNPs with variable RNA expression of  nearby genes (cis-
GWAS have linked SNPs to risk of inflammatory bowel disease (IBD), but a systematic 
characterization of disease-associated genes has been lacking. Prior studies utilized microarrays 
that did not capture many genes encoded within risk loci or defined expression quantitative trait 
loci (eQTLs) using peripheral blood, which is not the target tissue in IBD. To address these gaps, 
we sought to characterize the expression of IBD-associated risk genes in disease-relevant tissues 
and in the setting of active IBD. Terminal ileal (TI) and colonic mucosal tissues were obtained 
from patients with Crohn’s disease or ulcerative colitis and from healthy controls. We developed a 
NanoString code set to profile 678 genes within IBD risk loci. A subset of patients and controls were 
genotyped for IBD-associated risk SNPs. Analyses included differential expression and variance 
analysis, weighted gene coexpression network analysis, and eQTL analysis. We identified 116 genes 
that discriminate between healthy TI and colon samples and uncovered patterns in variance of gene 
expression that highlight heterogeneity of disease. We identified 107 coexpressed gene pairs for 
which transcriptional regulation is either conserved or reversed in an inflammation-independent or 
-dependent manner. We demonstrate that on average approximately 60% of disease-associated 
genes are differentially expressed in inflamed tissue. Last, we identified eQTLs with either 
genotype-only effects on expression or an interaction effect between genotype and inflammation. 
Our data reinforce tissue specificity of expression in disease-associated candidate genes, highlight 
genes and gene pairs that are regulated in disease-relevant tissue and inflammation, and provide a 
foundation to advance the understanding of IBD pathogenesis.
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eQTL) or distant genes (trans-eQTL) (4), deriving power from sample size and allele frequency of  the risk 
SNP (5). The largest eQTL analyses in IBD have focused on profiling peripheral blood (6). Studies of  cell 
type– and tissue-specific eQTL effects are just beginning to be reported for other complex immune-medi-
ated diseases (6–10). The first studies characterizing eQTLs in intestinal tissues from patients with IBD 
support disease and tissue specificity (11–13) but have been limited by sample size and exclusion of  patients 
with active IBD.
The goal of  this project was to characterize the differences in expression of  IBD-associated disease 
genes in uninflamed and inflamed regions of  the terminal ileum (TI) and colon from CD and UC patients 
(Figure 1). To permit study of  a large number of  mucosal tissues on a single transcriptomic platform, 
especially for the genes not covered by microarray platforms, we designed a NanoString code set with 678 
disease-associated genes (14) and generated expression profiles for more than 1,100 mucosal tissue samples 
from approximately 600 patients (Supplemental Tables 1 and 2; supplemental material available online 
with this article; doi:10.1172/jci.insight.87899DS1). A subset of  patients and controls were genotyped on 
the Illumina Immunochip array (15) with focused analysis of  IBD-specific risk loci.
Herein we present a quantitative analysis of  mRNA expression of  IBD-associated genes in disease-rel-
evant tissue. We identified a signature set of  116 genes that robustly discriminates between healthy TI and 
colon samples and validated that finding in an independent data set of  whole-genome transcriptomic pro-
files from normal mucosa. We observed that genes with the least variance in expression in healthy controls 
showed the greatest variance across uninflamed or inflamed TI and colon in patients with CD. We present 
Figure 1. Study design and analysis. The Sinai-Helmsley Alliance for Research Excellence (SHARE) consortium facilitated a 
multi-institutional collaboration for patient recruitment and sample collection, with centralized RNA expression profiling 
using NanoString technology, genotyping on the Immunochip array, and bioinformatics analysis. Samples were divided into 
3 analysis groups stratified by tissue type, disease type, and inflammation status, as shown in Supplemental Table 1. The 
analysis pipeline for RNA expression data included quality control, per-batch normalization, and cross-batch calibration. 
One hundred twenty-seven samples (11%) failed quality control. Eight hundred eighty-six samples, from 590 subjects 
who were genotyped, were selected for analysis. The final analysis cohort included 37 samples from healthy controls, 564 
samples from patients with Crohn’s disease, and 285 samples from patients with ulcerative colitis. Five distinct analyses 
were carried out with genotype and gene expression data. Location-specific expression patterns identified a gene signature 
that can discriminate between healthy colon and terminal ileum. Variance analysis examined the change in coefficient of 
variation as inflammation increases from healthy to disease state. Coexpression analysis identified both conserved and 
differentially coexpressed modules of genes using weighted gene coexpression network analysis. Differential expression 
and expression quantitative trait loci (eQTL) analysis used linear mixed-effects models to identify genes with significant 
regulatory patterns in inflammation of disease-specific tissue samples.
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an analysis supporting this finding that corrected for differences in sample size and confirmed this pattern 
to be true in age-matched patient samples. Using two distinct approaches to coexpression analysis, we 
identified gene modules in which the pairwise correlation structure was either conserved or differentially 
regulated from healthy to disease states. A detailed meta-analysis of  these modules led to identification of  
gene pairs for which either the correlation structure was conserved independent of  inflammation or the 
pattern of  paired regulation was inverted from healthy to disease states. A systematic differential analysis 
revealed shared and/or unique genes that were upregulated or downregulated along the spectrum from 
healthy to uninflamed and inflamed states in the setting of  active IBD. On average, we found approximately 
60% of  disease-associated genes to be differentially expressed in inflamed tissue relative to healthy tissue. 
Last, we identified eQTLs that were either characterized as having a genotype-only effect on expression 
independent of  disease, tissue type, and inflammation status or as exhibiting an interaction effect between 
genotype and inflammation.
Results
IBD risk genes exhibit segmental specificity of  expression between TI and colon across healthy controls. Clinically, 
UC is understood to be a colon-specific disease, whereas CD can cause disease anywhere along the gas-
trointestinal tract with a predilection for the TI in most adult patients. However, the question of  whether 
IBD-associated risk genes demonstrate segmental differential expression between the TI and colon has 
not been previously addressed. Using tissues from the TI, ascending colon, and descending colon of  37 
healthy individuals, 116 genes of  the 678 genes on our code set showed significant differential expression 
(FDR-adjusted q ≤ 0.05) according to tissue site (Figure 2A; complete heatmap, Supplemental Figure 1). 
The ascending and descending colon did not segregate independently. The colon-specific genes were not 
enriched for UC-specific genes, and the TI-specific genes were not enriched for CD-specific genes, but there 
were some notable exceptions, such as FAM55D. Encoded in a UC-specific risk locus (rs561722), FAM55D 
showed a 180- to 190-fold increase in relative expression in the colon versus the TI (q = 0.006); FAM55D 
is a member of  a family of  neurexophilin and may function as a neuropeptide, but its activity in the colon 
has not been studied.
To validate these tissue-specific profiles in an independent microarray analysis of  TI and colon tissues, 
we used a publicly available transcriptomic profile of  normal mucosa from 12 control subjects (6 colon and 
6 TI; ref. 16). Using gene set enrichment analysis, we found a marked enrichment (FDR q = 0.008) of  our 
colon upregulated gene set in the independent colon samples (Figure 2B). Likewise, the TI-specific genes 
were enriched in TI samples (FDR q = 0.005; Figure 2C). To further confirm this enrichment, we directly 
compared the number of  significantly upregulated or downregulated genes in both data sets and found that 
51 of  our signature genes (26 upregulated and 25 downregulated) were also significantly regulated in the 
independent set (P = 0.0045 and P = 0.0013, respectively; hypergeometric test). This differential expression 
analysis of  IBD-associated genes between TI and colon identifies tissue-specific marker genes and can 
inform hypotheses to further characterize distinctions observed between the TI and colon (17, 18).
IBD risk genes show low variance in expression across healthy controls with loss of  expression constraint in CD. 
We next examined the interindividual variation in gene expression within patient and control groups and 
asked how this changed in the setting of  disease. Conceptually, we hypothesized that if  these disease-asso-
ciated genes were important to maintaining intestinal homeostasis, gene expression variance would be con-
strained in healthy controls, whereas variance in patients would be increased, reflecting a loss in homeo-
static balance.
To examine these questions, we first looked at the average expression per sample (mean over all 678 
genes) and found that the average expression increased from healthy to disease uninflamed and inflamed 
samples (Figure 3A and Supplemental Figure 2, A and D; P values assessed by a linear mixed-effects model). 
Intragroup pairwise correlation between samples was consistently high within the healthy control group but 
dropped from as high as 0.96 to 0.45 between disease inflamed samples (Figure 3B and Supplemental Figure 
2, B and E). Within a group, the more highly expressed genes were associated with decreasing coefficient of  
variation (Figure 3C and Supplemental Figure 2, C and F). The global distribution of  average gene expression 
per gene was the same across all three groups (Supplemental Figure 2, G–H). To test for differences in vari-
ance independent of  confounding effects of  batch number or source institutions, we fit a linear mixed-effects 
model for each gene and examined the coefficient of  variation of  residuals for each gene and the fold change 
in coefficient of  variation in disease uninflamed or inflamed setting with respect to the baseline healthy state.
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Figure 2. Characterization of mucosal gene expression of inflammatory bowel disease risk genes in healthy terminal ileum and colon tissues. (A) In 
healthy controls, a unique set of genes is differentially expressed in the terminal ileum (TI) versus colon, but not between ascending and descending 
colon, suggesting tissue specificity between TI and colon, but not specific expression in the ascending or descending colon. The heat map is colored in 
a row-normalized fashion, i.e., red indicates the highest value for that specific gene, and blue indicates the lowest value for the same gene. Statistical 
significance of genes between TI samples (n = 13) and colon samples (n = 24) was estimated by computing the signal-to-noise ratio statistic. Genes 
with FDR-adjusted P values of ≤0.05 and signal-to-noise ratios >0.9 (absolute value) were selected as significant. The top 25 upregulated and down-
regulated significant genes are shown. (B and C) Using a publicly available microarray data set (GSE16879) for gene expression from 6 healthy TI and 
colon samples, the differential signature of 116 genes between healthy colon and TI was tested for significance as independent validation. Colon-spe-
cific upregulated genes were enriched and upregulated in the colon samples (FDR q = 0.008; gene set enrichment analysis [GSEA] P = 0.0045, hyper-
geometric test), whereas the TI-specific upregulated genes were enriched in the downregulated genes from the colon samples (FDR q = 0.005; GSEA P 
= 0.0013, hypergeometric test). The GSEA-based enrichment score (ES) reflects the degree to which a gene set is overrepresented at the top or bottom 
of a ranked list of genes. GSEA calculates the ES by going down the ranked list of genes, increasing a running-sum statistic when a gene is in the 
gene set and decreasing it when it is not. The magnitude of the increment depends on the correlation of the gene with the phenotype. The ES is the 
maximum deviation from 0 encountered in going down the list. A positive ES indicates gene set enrichment at the top of the ranked list; a negative ES 
indicates gene set enrichment at the bottom of the ranked list.
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The key finding of  this analysis was the demonstration that the genes with the lowest variance in the 
healthy control TI and colon samples exhibited the greatest increase in variance in CD patient TI (Figure 
3D) and colon samples. This pattern was confirmed when we selected only age-matched patients across 
three subgroups (Supplemental Figure 2I). We examined the complementary question of  the relationship 
between the genes with the lowest variance in CD and the fold change in variance in healthy controls and 
did not find the same pattern (Supplemental Figure 3, A and B).This trend was significant (P = 2.32E-92 
for uninflamed CD TI vs uninflamed healthy samples, and P = 4.15E-98 for inflamed CD TI vs uninflamed 
healthy samples) when paired changes in genes were collectively tested with a nonparametric paired Wil-
coxon rank test. To validate that this observation was not an artifact due to differences in sample sizes 
between the three groups, we randomly downsampled an equal number of  samples from the three groups 
1,000 times. For each random subsampling, we recomputed the linear mixed-effects models and subse-
quent residuals to examine whether our hypothesis of  increase in variance from healthy to disease states 
remained robust (Supplemental Figure 4A). Under these strict statistical parameters, we found that our 
hypothesis remained robust for the TI and colon samples from CD patients but did not meet statistical sig-
Figure 3. Variance of gene expression increases in patients with Crohn’s disease. (A) Average gene expression (per sample) increases from healthy ter-
minal ileum (TI) (n = 13) to Crohn’s disease (CD) uninflamed TI (n = 156) to CD inflamed TI (n = 152). P value was assessed by a linear mixed-effects model. 
(B) Pairwise Pearson’s correlation decreases from healthy controls to CD uninflamed TI to CD inflamed TI (mean, interquartile range), with associated 
decrease in pairwise correlation supporting increased variance in disease groups. (C) Within groups, genes with the highest average expression show the 
lowest coefficient of variation (per gene) in TI. (D) Of the genes with the lowest coefficient of variation in TI in the healthy state, these genes demonstrate 
the greatest fold change coefficient of variation in the uninflamed or inflamed state in CD; therefore, the genes with the tightest regulation across healthy 
controls show the greatest heterogeneity in expression in disease. P value was estimated by a nonparametric paired Wilcoxon test using all 678 genes.
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nificance in the UC patient samples (Supplemental Figure 4B). This finding suggests that mechanisms exist 
to tightly regulate the expression of  these disease-related genes and maintain them at homeostatic levels. 
The increased variance of  expression in disease states may reflect a loss of  such regulatory mechanisms.
Coexpression network analysis uncovers modules of  genes that are conserved or differentially expressed across tissue 
and inflammation phenotypes in CD and UC. We next investigated the pairwise correlation structure among 
all genes and how those relationships are perturbed in disease. We hypothesized that if  we could find a set 
of  genes that were correlated and coclustered in all the samples, then this group of  genes could be under a 
common transcriptional regulation program. Likewise, pairs of  genes that were differentially coexpressed 
and for which the correlation structure changed from the healthy state to disease uninflamed or inflamed 
states would be equally informative. Importantly, members of  these coexpression networks could suggest 
testable hypotheses for novel interactions and functions of  disease genes for which limited functional char-
acteristics are known.
We applied weighted gene coexpression network analysis (WGCNA) (19) to 8 data groups stratified by 
disease, tissue type, and inflammation status (Supplemental Figure 5). We used all 678 genes for consensus 
eigengene network detection. Briefly, the method uses correlation patterns between genes to construct net-
works of  independent data sets and then uses consensus dissimilarity clustering to identify preserved mod-
ules. As shown in Supplemental Figure 6, transcripts were clustered into distinct groups, herein referred 
to as modules, using dynamic tree cutting. We identified 5 distinct gene modules, which we have depicted 
with arbitrary colors (blue, brown, green, turquoise, and yellow; Supplemental Figure 6). Gene expression 
per module was further condensed into eigengene expression (first principal component), and the correla-
tion of  each gene to its eigengene expression was quantified (kME). The closer kME is to 1 or –1, the stron-
ger the evidence that the gene is part of  that module. The number of  genes included in the modules ranged 
from 50 (green) to 180 (turquoise), and their mean kME values ranged from 0.2349 (blue) to 0.4698 (green). 
As shown in Supplemental Figure 7, preservation of  consensus module eigengenes networks between any 
two data groups ranged from 0.55 to 0.93. To further identify pairs of  hub genes for which the correlation 
structure was conserved across all data groups, we identified gene pairs for which (a) the correlation scored 
in the top 1 percentile compared with the null distribution of  all pairwise correlation coefficients (Supple-
mental Figure 8), (b) the kME value for at least one of  the genes in the pair scored in the top 1 percentile 
compared with the null distribution (Supplemental Figure 9), and (c) the FDR-adjusted P value of  correla-
tion was ≤ 0.05 in all 8 data groups. This analysis resulted in a network of  33 genes, with 73 paired gene 
interactions (Figure 4A and Supplemental Table 3).
This conserved network showed the greatest enrichment for the T and B cell receptor signaling path-
way (Figure 4B; q = 7.8E-12 and 3E-4) by gene set overlap analysis and enrichment for ETS2 transcrip-
tion factor–binding sites (Figure 4C; q = 2.54E-9). Upregulation of  genes with ETS2-binding sites has 
been reported in UC patients (20). Among all 33 genes in this network, the top 3 genes with highest num-
ber of  conserved correlations were SP140, ARHGAP30, and ARHGAP9. The two isoforms of  SP140 them-
selves were most highly correlated (average correlation 0.91; turquoise module; Supplemental Table 3), 
followed by the gene pair SP140 and IKZF3 (average correlation 0.88; Figure 5 and Supplemental Figure 
10). SP140 contains a bromodomain and a plant homeodomain that recognize and bind acetylated and 
methylated histones, respectively, and are found in multiple epigenetic “readers” (21). SP140 is hypothe-
sized to act in immune tolerance or acute viral immunity (22). IKZF3 is important in lymphocyte differ-
entiation and proliferation, particularly in promoting Th17 differentiation (23). SP140 and IKZF3 share 
similar patterns of  tissue-specific expression, with the highest expression in the spleen, small intestine, 
and whole blood (24) as well as B cell subsets (25, 26). In addition to IBD, SNPs in both genes have been 
associated with risk for multiple sclerosis (27, 28).
The initial WGCNA analysis sought to relate genes through conserved correlation of  expression, 
regardless of  inflammation or tissue. We then asked the complementary question of  which correlation 
pairs may be changed in the setting of  inflammation compared with the healthy state. We applied a 
method called DiffCoEx (29) that builds on the WGCNA framework to identify differentially coex-
pressed gene modules separately in our three analysis sets (Supplemental Figures 11 and 12). We iden-
tified 35 differentially coexpressed modules (12 in CD TI data sets, 12 in CD colon data sets, and 11 
in UC colon data sets; Supplemental Table 4). The number of  genes in each module ranged from 24 to 
355. We did not find any differentially coexpressed modules when comparing UC inflamed TI samples 
to UC uninflamed TI samples.
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Figure 4. Network of 
correlated hub genes 
conserved across distinct 
data groups. (A) Gene 
pairs were selected 
based on significance 
of pairwise correlation 
across all data groups and 
high correlation of gene 
expression with eigengene 
profile (kME value). Genes 
are shown as nodes, and 
pairwise correlations are 
displayed as edges (red, 
positive correlation; blue, 
negative correlation). Larg-
er nodes denote higher 
kME values, and thicker 
edges represent stronger 
absolute correlations. (B 
and C) Gene set overlap 
analysis of conserved net-
work genes, as evaluated 
with Molecular Signa-
tures Database (MSigDB) 
database. P values 
were estimated using a 
hypergeometric test. FDR 
q values are plotted on 
a –log10 scale. Q value > 1.3 
is significant. Enrichment 
of pathways is shown in B. 
Enrichment for transcrip-
tion factor binding sites is 
shown in C.
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We further evaluated each of  these gene modules and identified transcription factors that were sig-
nificantly enriched and bind to the promoter regions of  genes (within –2 kb to +2 kb of  the transcrip-
tion start site) in these modules (Supplemental Table 5). Immune-regulated transcription factors were 
enriched across all modules, including NF-κB, REL, NFAT, STAT1, STAT3–STAT6, TCF1, TCF3, 
TCF8, IRF1, IRF2, IRF7, and IRF8. Notably, ELF1, ETS, NF-κB, and RUNX1, found to be enriched in 
one or more differentially coexpressed modules in our data, have been reported to be enriched with auto-
immune SNP variants that disrupt the binding site motif  for these transcription factors (27). Additional-
ly, nuclear receptors with known links to intestinal immunity and epithelial integrity, such as vitamin D 
receptor (VDR) (30–32), sterol regulatory element binding transcription factor 1 (SREBF1) (33, 34), and 
aryl hydrocarbon receptor nuclear translocator (ARNT) (35, 36), were also enriched in one or more mod-
ules. We observed the greatest change in number of  differentially coexpressed modules between healthy 
and disease states rather than between disease uninflamed and inflamed states.
To identify gene pairs within these modules with the most significant changes in pairwise cor-
relation coefficient across groups, we estimated (a) the empirical P value of  change in correlation 
with respect to null distribution of  all possible pairwise values of  change in correlation coefficient 
(Supplemental Figure 13–15) and (b) FDR-adjusted P values for all pairs of  genes. We identified 34 
gene pairs (36 unique genes) with significant changes in correlation from the healthy state to disease 
uninflamed and inflamed states (Supplemental Table 6). Recent studies offer insights into potential 
roles in IBD-relevant pathways for the proteins encoded by these genes, such as C1ORF106 in auto-
phagy-dependent intracellular pathogen defense (37) and C5ORF30 in negative regulation of  immune 
and inflammatory pathways (38), but the activities of  many of  the genes remain to be studied in the 
context of  IBD or other immune-mediated diseases.
In general, these networks represent clusters of  genes within which transcriptional regulation is simul-
taneously reprogrammed in the inflammatory state (example networks, Figure 6; example plots, Figure 7; 
and Supplemental Figure 16). As an example, SULT1A1 and SMAD3 were negatively correlated in healthy 
TI with higher expression of  SULT1A1 correlating with lower SMAD3 (Figure 7A); yet in CD, both in 
uninflamed and inflamed TI, the gene pair was positively correlated (Figure 7, B and C). SULT1A1 is a 
sulfotransferase important in xenobiosis, shown to be induced by TGF-β (and TNF-α) in a colon cancer cell 
line (39). This pair of  genes may be connected through TGF-β, given that SMAD3 is directly downstream 
of  TGF-β signaling, a pathway tied to fibrostenotic disease in CD, or another shared ligand. CD-associated 
risk alleles in SMAD3 have been associated with increased risk of  recurrent surgeries in CD (40), underscor-
ing its association with more severe disease (40). Further study will be required to understand the opposing 
correlation phenotypes between healthy and disease states.
Figure 5. Pairwise correlation between SP140 and IKZF3 conserved across data groups. Pairwise correlation between SP140 and IKZF3 is conserved 
across disease and tissue groups, independent of inflammation status. Expression correlation in terminal ileum (TI) tissue samples from (A) healthy 
controls, (B) Crohn’s disease (CD) uninflamed, and (C) CD inflamed groups, respectively. Linear Pearson’s correlation coefficient was estimated using 13 
healthy TI samples, 156 uninflamed CD TI samples, and 152 inflamed CD TI samples.
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Differential gene expression across patient groups compared with controls demonstrates disease- and tissue-specific 
patterns. We next evaluated the patterns of  distinct and overlapping expression of  risk genes, comparing 
CD and UC, to further characterize IBD-associated risk genes in disease-relevant tissues (Figure 8). We 
used linear mixed models to identify IBD-associated risk genes that were differentially expressed between 
the healthy state and disease uninflamed or inflamed states (Supplemental Figure 17). In this model, the 
uninflamed tissues from patients served as an intermediate state between healthy and inflamed tissues, in 
line with prior data supporting baseline expression differences in intestinal mucosal tissues devoid of  active 
inflammation in patients with IBD (41).
We found 385 differentially expressed genes in CD TI (example plots, Figure 8, A–C, and Supple-
mental Table 7), 431 in CD colon (example plots, Figure 8, D–F, and Supplemental Table 8), and 439 in 
UC colon (example plots, Figure 8, G–I, and, Supplemental Table 9) compared with the healthy state. In 
the colon, CD and UC shared a large set of  differentially expressed genes (~88%, 376 genes in common). 
The most significantly upregulated gene between healthy TI and CD TI was Fc γ receptor 3A (FCGR3A; 
FDR 3.18E-25; Figure 8A); additional upregulated gene family members included FCGR3B (FDR 4.30E-
24) and FCGR2A (FDR 1.99E-22), suggesting a potential common regulator in the TI. FCGR3A and 
FCGR3B are among the top 20 most significantly upregulated genes in a treatment-naive pediatric ile-
al CD population (41). FCGR3A (FDR 1.10E-17) and FCGR3B (FDR 7.56E-21; Figure 8D) were also 
upregulated in inflamed CD colon. Upregulation of  the decoy receptor for Fas ligand TNFRSF6B (FDR 
8.06E-26, Figure 8E) was found only in CD colon, not in CD TI. Exploring these unique patterns may 
shed light on similarities and differences between small intestine and colon inflammation.
Other findings included downregulation of  VDR in both UC (FDR 8.17E-21) and CD (FDR 5.18E-
18; Figure 8F). In patients, serum vitamin D concentrations and UC disease activity are inversely related 
(42). The role of  vitamin D in intestinal homeostasis has been shown through regulation of  autopha-
gy (43) and tight junctions (44). Genetic polymorphisms in VDR affect variations in serum vitamin D 
concentrations (45), and further studies have shown that VDR mediates microbe-host interactions (32). 
Consistent with a prior report (46), the cation/carnitine transporter SLC22A5 showed universal down-
regulation across CD TI (FDR 1.42E-12), CD colon (FDR 2.31E-16), and UC colon (FDR 1.37E-27; 
Figure 8H). Supplementation with carnitine, proposed to function as an antioxidant through fatty acid 
oxidation and immunosuppressive properties (47), has shown efficacy in treating UC (48).
In contrast to the large number of  differentially expressed genes found by comparing healthy and dis-
Figure 6. Network visualization of differentially coexpressed module changes in colon tissue of healthy and Crohn’s disease 
patients. (A) Differential coexpression module from healthy state to uninflamed Crohn’s disease (CD) state. (B) Differential 
coexpression module from healthy state to inflamed CD state. (C) Differential coexpression module from uninflamed CD state 
to inflamed CD state. Gene pairs were selected based on whether the Pearson’s correlation coefficient exhibited the most sig-
nificant change in all 3 pairwise comparisons between 3 data groups. For each module, genes are shown as nodes and pairwise 
correlations are displayed as edges (red, positive correlation; blue, negative correlation). Thicker edges represent stronger abso-
lute correlations. Linear Pearson’s correlation coefficient was estimated using 24 healthy colon samples, 177 uninflamed CD colon 
samples, and 79 inflamed CD colon samples.
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ease states, differential analysis of  uninflamed TI/colon samples from CD and UC patients yielded only 14 
significant genes (6 in TI and 8 in colon; Supplemental Table 10), suggestive of  CD versus UC specificity 
(Supplemental Figure 18). The gene with the greatest differential expression between the three groups was 
IFN regulatory factor 4 (IRF4), with the highest expression in uninflamed CD colon. IRF4 is a master 
transcription factor for Th17 cells (49) and CD11b+ dendritic cell differentiation that further drives Th17 
responses (50). Th17 cells play complex roles in IBD, with contributions to both inflammatory and immu-
noregulatory responses (51, 52). IRF4 is induced by NOD2 and negatively regulates the innate immune 
response by inhibiting the polyubiquitination of  RICK and TRAF6 to downregulate NF-κB, protecting 
mice from colitis in experimental models (53).
eQTL analysis highlights effects of  disease-associated genetic variation on gene expression. We conducted an eQTL 
analysis to examine how disease-associated variants regulate gene expression in gut tissue. We extended the 
linear mixed models from our differential expression analysis to include and test the effect of  genotype and 
the interaction between genotype and the independent variables of  disease, tissue type, and inflammation sta-
tus (Supplemental Figure 19) using samples from healthy controls and the uninflamed and inflamed samples 
from the CD and UC patient groups. The model merged patients and controls heterozygous or homozygous 
Figure 7. Pairwise correlations show differential directionality of correlation between controls and disease groups. SULT1A1 and SMAD3 show a correla-
tion coefficient of –0.71 in (A) healthy terminal ileum (TI) but are positively correlated in (B) uninflamed Crohn’s disease (CD) TI (rho 0.63) and (C) inflamed 
CD TI (rho 0.62). Linear Pearson’s correlation coefficient was estimated using 13 healthy TI samples, 156 uninflamed CD TI samples, and 152 inflamed CD TI 
samples. IRF1 and ULK3 show a correlation coefficient of 0.77 in (D) healthy colon but a negative correlation in (E) uninflamed ulcerative colitis (UC) colon 
(rho –0.17) and (F) inflamed UC colon (–0.32). Linear Pearson’s correlation coefficient was estimated using 24 healthy colon samples, 142 uninflamed UC 
colon samples, and 107 inflamed UC colon samples.
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Figure 8. Top differentially expressed genes across healthy controls and uninflamed and inflamed disease states. (A) FCGR3A (FDR = 3.1755E-25), (B) 
C10orf58 (FDR = 3.621E-21), and (C) CDH3 (FDR = 7.7048E-15) show the most statistically significant differential expression across healthy terminal ileum 
(TI), Crohn’s disease (CD) uninflamed TI, and CD inflamed TI. A linear mixed-effects model was used to estimate significance of difference in gene expres-
sion. Genes with FDR adjusted P values of ≤0.05 were considered significant. 13 healthy TI samples, 156 uninflamed CD TI samples, and 152 inflamed CD 
TI samples were used for this analysis. (D) FCGR3B (FDR = 7.5608E-21), (E) TNFRSF6B (FDR = 8.0625E-26), and (F) VDR (FDR = 5.18E-18) show the most 
statistically significant differential expression across healthy colon, CD uninflamed colon, and CD inflamed colon. A linear mixed-effects model was 
used to estimate significance of difference in gene expression. Genes with FDR adjusted P values of ≤0.05 were considered significant. 24 healthy colon 
samples, 177 uninflamed CD colon samples, and 79 inflamed CD colon samples were used for this analysis. (G) XBP1 (FDR = 1.0615E-30), (H) SLC22A5 (FDR 
= 1.3705E-27), and (I) PRDM1 (FDR = 6.4835E-20) show the most statistically significant differential expression across healthy colon, ulcerative colitis 
(UC) uninflamed colon, and UC inflamed colon. A linear mixed-effects model was used to estimate significance of difference in gene expression. Genes 
with FDR-adjusted P values of ≤0.05 were considered significant. 24 healthy colon samples, 142 uninflamed UC colon samples, and 107 inflamed UC colon 
samples were used for this analysis.
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for the IBD-associated risk allele compared with those homozygous for the non-risk allele. Candidate eQTLs 
were selected based on P values of  coefficients for select variable terms (genotype and interaction terms) in 
the linear model and further validated by independently permuting genotype and gene expression 1,000 times 
(Supplemental Figure 20). We identified 34 eQTLs that were categorized to have a genotype-only effect, an 
interaction-only effect, or both. Key significant eQTLs, with tissue and disease specificity and associated P 
values, are shown in Figure 9; all eQTLs are provided in Supplemental Table 11.
The identified eQTLs include examples of  differential gene expression driven only by genotype (geno-
type effect) and others in which the eQTL effect emerges in the setting of  inflammation (interaction effect). 
The eQTL effect between rs1363907 and endoplasmic reticulum aminopeptidase 2 (ERAP2), which plays 
a central role for peptide trimming and antigen presentation on major histocompatibility complex I, is one 
example of  genotype-only effect across CD TI (Figure 9A), CD colon (Figure 9D), and UC colon (Figure 
9G). This finding replicates an eQTL previously reported in ileal (11) and colonic tissue (12, 13). Our 
data extend these previous findings by describing how the inflammatory state changes ERAP2 expression 
(increased in CD colon and UC colon with inflammation but unchanged by inflammation in the CD TI). 
Illustrating how this analysis builds on prior eQTL studies and incorporates the effect of  inflammation, the 
genotype-only eQTLs can be correlated with the interaction-only effect of  rs10758669 and B cell scaffold 
protein with ankyrin repeats 1 (BANK1), in which BANK1 expression is increased in the setting of  inflam-
mation in CD TI for individuals heterozygous or homozygous for the risk allele, whereas expression is 
decreased in those homozygous for the non-risk allele (Figure 9B). This eQTL analysis serves to illustrate 
how disease-associated genetic variants effect gene expression in the gut and in the setting of  active disease.
Discussion
An important challenge in the GWAS era is the harnessing of  knowledge gained by understanding the 
genetic risk of  disease to inform studies of  intestinal homeostasis and IBD pathophysiology. Using tissue-, 
disease-, and inflammation-specific differential expression, coexpression, and eQTL analysis, we sought to 
characterize the expression of  candidate genes in IBD-associated risk loci.
Our approach addressed feasibility challenges inherent to studying a large number of  genotyped 
patients with tissue samples, making it possible to examine differences between CD and UC, uninflamed 
and inflamed tissues, and TI and colon, all on the same transcriptomic platform. Our data highlight the seg-
mental expression of  IBD-associated risk genes across the TI and colon. The coexpression analysis demon-
strates how disease-associated genes are interrelated and how these gene-gene relationships are changed in 
the setting of  IBD. Multiple studies have suggested that coexpressed genes share similar biological function 
(54) with biological drivers of  coexpression (and tissue-specific patterns), including transcription factors, 
spatial configuration of  chromosomes, mRNA degradation, miRNAs, and epigenetic modulation (55, 56); 
we too found pathway and transcription factor enrichment (Figure 4) within our network of  correlated hub 
genes conserved across tissue types.
We expanded traditional differential expression analyses by examining variance of  expression between 
healthy controls and patients with IBD. The inclusion of  healthy controls permitted exploration of  how 
the genes are expressed in health, representing a state of  homeostasis. The age of  the healthy control 
population was older than that in the disease group, yet in a subgroup analysis of  age-matched patients 
only, our significant observations, including the change in variance, followed the same trends (Supplemen-
tal Figures 2I and 21–24). One model in the literature suggests that disease-associated genes demonstrate 
greater stochastic variation in health (57), and alterations in variance can define disease phenotypes (58); 
yet these questions have not been examined in the context of  the gut or IBD. After accounting for batch 
and institutional effects, we considered cellular heterogeneity as a potential driver of  the increased variance 
in CD patients; however, two observations argue that heterogeneity in cellular composition is unlikely to 
explain this finding. First, we found that the observation was also true in the uninflamed tissues, in which 
the cellular composition more closely aligns with healthy tissue. Second, the trend of  increased variance 
did not hold in the UC patients, in which cellular heterogeneity would be present in the inflamed samples. 
These data, coupled with the differential expression data, particularly in the uninflamed samples compared 
with the healthy controls, suggest that the IBD-associated risk genes are important in intestinal homeostasis 
and exhibit perturbed expression, even in the uninflamed state in patients with IBD. The variance in gene 
expression suggests that these genes are otherwise held under tight regulatory constraints that are lost in 
the setting of  CD and may represent a novel phenotypic marker of  disease. Although consensus clustering 
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analysis in this data set failed to elucidate subgroups, we envision that whole-genome transcriptomic pro-
files will be better equipped to identify subgroups of  patients.
Demonstrating the value of  a tissue- and disease-based approach to study the effects of  disease-asso-
ciated genetic variation, this work has relevance to other complex, multigenic autoimmune and inflam-
Figure 9. Top expression quantitative trait loci (eQTL) identified with genes demonstrating differential expression across healthy controls and disease 
groups. Log2 gene expression depicted in blue corresponds to healthy controls and patients homozygous for the inflammatory bowel disease–associated 
(IBD-associated) non-risk allele; log2 gene expression depicted in red corresponds to healthy controls and patients heterozygous or homozygous for the 
IBD-associated risk allele. A linear mixed-effects model was used to estimate significance of effect of genotype only and interaction of genotype with tissue 
inflammation status on gene expression. Genes with P values of ≤ 0.05 for one of the three terms (genotype, tissue inflammation status, or interaction term) 
were considered significant. Significance was further validated by permuting genotype and gene expression independently 1,000 times each. 13 healthy termi-
nal ileum (TI) samples, 156 uninflamed Crohn’s disease (CD) TI samples, 152 inflamed CD TI samples, 142 uninflamed ulcerative colitis (UC) colon samples, and 
107 inflamed UC colon samples were used for this analysis. Genotype-only effects are shown in A, D, G, and H; interaction-only effects are shown in B, C, E, F, 
and I. rs1363907 and ERAP2 show the strongest cis-eQTL effect across tissue and disease groups (TI shown in A, colon shown in D and G).
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matory diseases. Refining candidate genes in IBD and autoimmune/autoinflammatory disease-associated 
risk loci has advanced by exome-sequencing studies, fine mapping of  high confidence risk loci, and eQTL 
analysis (27, 59–61). However, the major integrative analyses with eQTLs, such as those for rheumatoid 
arthritis (61), systemic lupus erythematosus (62), and multiple sclerosis (63), have used eQTLs defined in 
peripheral blood (64) or immune cell subsets (63, 65). eQTL mapping in neutrophils (66, 67), monocytes 
(10), and dendritic cells (68) has expanded by comparing resting cells with cells after immune stimulation. 
These “induced” or “response” eQTLs are enriched for GWAS-identified loci, supporting the hypothesis 
that these loci have context-specific (including inflammation-specific) effects. The approach employed in 
our work allowed for a demonstration of  how genetic variation affects differential gene expression under in 
vivo inflammatory conditions in disease-relevant tissues.
Taken together, these data reinforce the tissue specificity of  gene expression in IBD-associated risk loci 
and the value of  studying genes in the context of  intestinal tissue and IBD-associated inflammation. We 
offer these data, grounded in our understanding of  the genetic susceptibility to disease, tissue-based differ-
ential expression, and eQTL effects, to prioritize candidate genes and to inform future functional studies 
that will use genetics to advance the understanding of  IBD pathogenesis (Supplemental Table 12).
Methods
Patient recruitment and sample collection. Prospectively recruited patients and archived patient samples were 
collected at 5 academic institutions throughout the United States. Patients were recruited after a known 
diagnosis of  CD or UC. Healthy controls were recruited at time of  routine colonoscopy and were con-
sidered healthy if  they reported no history of  gastrointestinal symptoms (abdominal pain or diarrhea) for 
>1 day per week in past 6 months, no history of  IBD or irritable bowel syndrome, no history of  asthma 
or autoimmune disease, and no personal or family history of  colon cancer. At the time of  biopsy, healthy 
controls had a median age of  59 years, within a range of  42–69 years of  age. Median age for patients at 
the time of  biopsy was 39–40 years, but patients had a much larger age range that spanned from 15 to 79 
years and included individuals in most decades in this range. Blood was banked for DNA extraction and 
genotyping. At the time of  endoscopy, mucosal biopsies were collected in RNAlater (Qiagen) and stored 
at –80°C ahead of  downstream processing. If  samples were collected at the time of  surgery, mucosal tissue 
samples obtained from bowel resection specimens with colonoscopic biopsy forceps were processed imme-
diately or stored at 4°C for processing within 12 hours. Intestinal source location and inflammation status 
was indicated as “uninflamed” or “inflamed” based on the endoscopic or gross appearance of  the tissue by 
the endoscopist or investigator at time of  surgical specimen collection. All biospecimens were gifted with 
patient consent (see Study approval) for this study by coinvestigators (R. Balfour Sartor, Rodney D. Newber-
ry, Dermot P. McGovern, Vijay Yajnik, Sergio A. Lira, and Ramnik J. Xavier).
Genotyping. Genomic DNA was extracted from buffy coats, with genotyping performed at the Broad 
Institute or Cedars-Sinai Medical Center on the Illumina Immunochip array containing 196,806 SNPs and 
718 small insertions/deletions associated with 11 autoimmune or inflammatory diseases (15). Five hun-
dred and ninety-three patients were genotyped on this platform. For this study, we restricted our analysis 
to the 163 SNPs identified as associated with CD, UC, or both diseases as previously published (1) and 
focused transcriptional analysis as described below. Of  the 163 SNPs, 159 SNPs passed QC (genotyping 
call rate >99%, minor allele frequency >5%) on both genotyping platforms and were included in down-
stream analysis.
Tissue total RNA extraction or cell lysis. More than 1,100 tissue samples were collected. Using a com-
bined TRIzol (Life Technologies) and chloroform extraction and the RNeasy Midi Kit (Qiagen) for RNA 
extraction, total RNA was extracted by the manufacturer’s protocol, and RNA purity and quantity was 
measured by NanoDrop spectrophotometer (Promega).
NanoString code set construction. The custom NanoString probe set targeted 678 unique genes, including 
15 housekeeping genes (Supplemental Table 2). Of  these genes, 156 (23%) were not captured on the Agilent 
microarray platform that was used in the largest published microarray study examining gene expression in 
IBD (2, 3). Four-hundred and sixty-three of  the genes fall within a 500-kb window flanking a tagged risk 
SNP as previously published (1). We prioritized these genes from the >1,400 genes encoded within the loci 
based on known expression patterns in cell types of  interest in IBD (e.g., intestinal epithelium, immune 
cell types), functional annotation where available, and genes previously implicated in eQTL analyses in 
previous studies. The core set of  IBD-associated risk genes on the code set was taken directly from the 
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prioritized genes in the Jostins et al. IBD GWAS meta-analysis (1). The additional genes in the probe set 
were selected for activity in the immune response and in inflammation, with emphasis on genes implicated 
in type 1 diabetes and celiac disease, given the genetic overlap in susceptibility loci for these diseases (1, 69) 
(Supplemental Table 2, for a few select genes, we added probes for multiple isoforms of  the same genes and 
these are named as *_v1 or *_v2).
NanoString gene expression profiling. Extracted RNA was used as input for expression profiling by NanoS-
tring. All samples were prepared according to the manufacturer’s specifications (NanoString Technologies). 
Briefly, input RNA (100 ng) was hybridized with reporter probes to specific transcript tags in a multiplexed 
ligation reaction using reverse complementary bridge oligonucleotides. Spiked-in controls (in addition to 
housekeeping genes) were used in each reaction to permit normalization. After the ligation reaction, tagged 
transcripts were hybridized to tag-specific capture probes with attached fluorescent bar codes by incuba-
tion at 65°C for 14 to 28 hours. Excess probes were removed on the nCounter Prep Station according to 
the manufacturer’s instructions (NanoString Technologies), and the captured, transcript-specific, bar-coded 
ternary complexes were immobilized on a streptavidin-coated cartridge. The individual bar codes were 
counted on the nCounter Digital Analyzer (NanoString Technologies) using a high density of  fields of  view 
(>600) to quantify target RNA molecules present in the sample. Data are accessible in the GEO database 
under accession number GSE73094.
NanoString data normalization. NanoString gene expression profiles were generated using 3 distinct 
versions of  the probe sets over a span of  3 years. Explicit normalization was required to correct for 
probe version and batch-level differences. This was achieved by a 2-stage normalization process. In 
the first stage, each lot of  data pertaining to a specific version of  the probe set was normalized inde-
pendently using the following 6 steps. (a) Background noise was estimated using mean expression 
levels of  spiked-in negative controls. (b) Estimated noise value was subtracted from raw counts data 
for each sample. Negative count values were reset to 1. (c) Count values of  spike-in positive controls 
were summed per sample, and the average value was used to estimate a scaling factor for each sample. 
The expression value of  each sample was adjusted using the sample-specific normalization factor. (d) 
Samples with higher than acceptable background noise and positive control-based scaling factors of  
<0.3 or >3.0 were identified as outliers and removed from analysis. (e) Next, the geometric mean of  
housekeeping genes was computed for each sample, and the average value was used to compute the 
normalization factor. Data were adjusted in a similar fashion as was done previously with spiked-in 
positive controls. (f) Finally, samples with housekeeping gene–based normalization factors of  <0.2 
or >5.0 were removed as outliers. In the second stage of  normalization, data generated from first 
version of  probe sets (batch 1) were chosen as the common reference to which the remainder of  the 
data (batches 2 and 3) were independently calibrated using a small set of  samples that were repeatedly 
profiled in all 3 lots. This was achieved with the following steps. (a) The average of  medians of  calibra-
tion samples, for a given pair of  lots, was computed and used to estimate the normalization factor for 
each sample. (b) Each lot was scaled with the normalization factor computed in the previous step. (c) 
Geometric means of  counts per gene among repeated samples was computed within a lot, and a cal-
ibration factor was estimated per gene (4). Calibration for each gene was applied to the nonreference 
lot. All computations were performed in MATLAB. Nine hundred and eighty-nine samples passed 
data normalization and quality control.
Statistics. Statistical significance of  genes between TI and colon samples was estimated by computing 
the signal-to-noise ratio statistic. Genes with FDR-adjusted P values of  ≤0.05 and signal-to-noise ratios of  
>0.9 (absolute value) were selected as significant. Healthy TI and colon samples profiled on our NanoS-
tring platform were compared with microarray profiles of  TI and colon samples from healthy (control) indi-
viduals used in a publicly available data set (GSE16879) (16). Normalized and log2-transformed data from 
the selected 560 genotype patients, amounting to 886 samples, were stratified by disease, tissue type, and 
inflammation status (Figure 1). Three analysis groups were formed: (a) healthy versus CD uninflamed and 
inflamed TI samples, (b) healthy versus CD uninflamed and inflamed colon samples, and (c) healthy versus 
UC uninflamed and inflamed colon samples (Supplemental Table 1). Analysis of  coefficient of  variation, 
consensus coexpression, differential coexpression, differential expression, and eQTLs was conducted as 
outlined in Supplemental Figures 4, 5, 11, 17, and 19, respectively. FDR-adjusted P values, estimated by the 
Benjamini-Hochberg method, were used in all analysis unless stated otherwise. The threshold for signifi-
cance was FDR-adjusted P value ≤ 0.05.
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